D. E. Shaw & Co., Inc. Humanigen, Inc Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $518,210 - $980,478	-294,438 Reduced 45.49%	352,853 $624,000
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $351,516 - $771,005	194,208 Added 42.86%	647,291 $1.95 Million
Q4 2021 Feb 14, 2022	SELL	$3.66 - $8.22 $60,283 - $135,391	-16,471 Reduced 3.51%	453,083 $1.69 Million
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $1.02 Million - $3.06 Million	171,856 Added 57.73%	469,554 $2.78 Million
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $4.03 Million - $6.77 Million	297,698 New	297,698 $5.17 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.